Musclepharm Revenue Growth Rates (MSLP), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Musclepharm Corporation  (MSLP)
 

MSLP's Revenue Growth by Quarter and Year

Musclepharm's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MSLP Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 13.10
FY 13.10

MSLPs Annual Revenue
Musclepharm's Revenue in the fiscal year 2021 $ 50.04 millions
Musclepharm's Revenue in the fiscal year 2020 $ 64.44 millions
Musclepharm's Revenue in the fiscal year 2019 $ 79.67 millions
Musclepharm's Revenue in the fiscal year 2017 $ 102.16 millions
Musclepharm's Revenue in the fiscal year 2016 $ 132.50 millions




MSLP Revenue first quarter 2022 Y/Y Growth Comment
Musclepharm Corporation reported decrease in Revenue in the first quarter 2022 by -0.14% to $ 13.10 millions, from the same quarter in 2021.
The decrease in the first quarter 2022 Musclepharm Corporation's Revenue compares unfavorably to the Company's average Revenue rise of 22.42%.

Looking into first quarter 2022 results within Major Pharmaceutical Preparations industry 167 other companies have achieved higher Revenue growth. While Musclepharm Corporation' s Revenue decline of -0.14% ranks overall at the positon no. 2883 in the first quarter 2022.


MSLP Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December - -33.64 % -13.15 % -13.59 %
3rd Quarter September - -25.61 % -24.03 % -3.46 %
2nd Quarter June - -12.24 % -23.81 % 2.15 %
1st Quarter March -0.14 % -19.16 % -13.58 % -22.36 %
FY   - -22.35 % -19.13 % -

Financial Statements
Musclepharm's first quarter 2022 Revenue $ 13.10 millions MSLP's Income Statement
Musclepharm's first quarter 2021 Revenue $ 13.12 millions Quarterly MSLP's Income Statement


MSLP Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - -16.12 % -5.97 % -17.75 %
3rd Quarter September - -19.72 % -5.3 % -5.02 %
2nd Quarter June - 13.64 % 4.68 % 18.74 %
1st Quarter March 30.49 % -13.28 % -6.83 % -6.85 %
FY (Year on Year)   - -22.35 % -19.13 % -


Back to MSLP Growth rate Comparisons >> Back to MSLP Growth rate Comparisons >>


Revenue first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #168
Healthcare Sector #428
Overall #2883

Revenue Y/Y Growth Statistics
High Average Low
354.11 % 22.42 % -39.39 %
(Jun 30 2012)   (Mar 31 2017)
Revenue first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #168
Healthcare Sector #428
Overall #2883
Revenue Y/Y Growth Statistics
High Average Low
354.11 % 22.42 % -39.39 %
(Jun 30 2012)   (Mar 31 2017)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Musclepharm's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
47.93 % 0.18 % -100 %
(Dec 31 2013)  


MSLP's I. Quarter Q/Q Revenue Comment
Musclepharm Corporation achieved in the I. Quarter 2022 above company average sequential Revenue jump of 30.49%, to $ 13.10 millions, from $10.04 millions in the fourth quarter.
MSLP is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 60 other companies have achieved higher Revenue quarter on quarter growth. While Musclepharm's Revenue growth quarter on quarter, overall rank is 413.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #61
Healthcare Sector #114
Overall #413
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #61
Healthcare Sector #114
Overall #413
Revenue Q/Q Growth Statistics
High Average Low
47.93 % 0.18 % -100 %
(Dec 31 2013)  


MSLP's I. Quarter Q/Q Revenue Comment
Musclepharm Corporation achieved in the I. Quarter 2022 above company average sequential Revenue jump of 30.49%, to $ 13.10 millions, from $10.04 millions in the fourth quarter.
MSLP is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 60 other companies have achieved higher Revenue quarter on quarter growth. While Musclepharm's Revenue growth quarter on quarter, overall rank is 413.


Musclepharm's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)		 12 Months Ending
(Jun 30 2021)		 12 Months Ending
(Mar 31 2021)
Cumulative Revenue 12 Months Ending $ 50.02 $ 50.04 $ 55.13 $ 59.25 $ 61.33
Y / Y Revenue Growth (TTM) -18.44 % -22.34 % -17.38 % -17.51 % -20.48 %
Year on Year Revenue Growth Overall Ranking # 3431 # 3469 # 2930 # 2879 # 3458
Seqeuential Revenue Change (TTM) -0.04 % -9.23 % -6.94 % -3.4 % -4.83 %
Seq. Revenue Growth (TTM) Overall Ranking # 3164 # 3542 # 3240 # 3157 # 3111


Cumulative Revenue growth Comment
Musclepharm showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2021. If the fiscal year would end in Mar 31 2022, Musclepharm's annual Revenue decline would be -18.44% year on year to $50 millions.

In the Healthcare sector 468 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3431, from total ranking in previous quarter at 3469.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 150
Healthcare Sector # 469
Overall # 3431

Revenue TTM Y/Y Growth Statistics
High Average Low
102.73 %
 2.21 %
-31.38 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 150
Sector # 427
S&P 500 # 3164
Cumulative Revenue growth Comment
Musclepharm showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2021. If the fiscal year would end in Mar 31 2022, Musclepharm's annual Revenue drop would be -18.44% year on year to $50 millions.

In the Healthcare sector 468 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3431, from total ranking in previous quarter at 3469.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 150
Healthcare Sector # 469
Overall # 3431

Revenue TTM Y/Y Growth Statistics
High Average Low
102.73 %
2.21 %
-31.38 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 150
Sector # 427
S&P 500 # 3164




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MSLP's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2022
Sage Therapeutics Inc -0.06%$ -0.063 millions
Davita Inc -0.09%$ -0.087 millions
Axogen inc -0.10%$ -0.097 millions
Musclepharm Corporation-0.15%$ -0.152 millions
3m Company-0.25%$ -0.249 millions
Oncternal Therapeutics Inc -0.27%$ -0.267 millions
Glaukos Corp-0.42%$ -0.422 millions
Collegium Pharmaceutical Inc -0.70%$ -0.699 millions
Tenet Healthcare Corp-0.75%$ -0.753 millions
Nevro Corp -0.87%$ -0.867 millions
Antares Pharma Inc -1.25%$ -1.250 millions
Assure Holdings Corp -1.34%$ -1.343 millions
Elanco Animal Health Incorporated-1.37%$ -1.369 millions
Longeveron Inc -1.60%$ -1.596 millions
Rockwell Medical inc -1.67%$ -1.674 millions
Nanostring Technologies Inc -1.70%$ -1.698 millions
Mimedx Group Inc -1.79%$ -1.789 millions
Exagen Inc -1.82%$ -1.823 millions
Cryoport inc -1.84%$ -1.843 millions
Royalty Pharma Plc-1.92%$ -1.916 millions
Veru Inc -2.34%$ -2.339 millions
Femasys Inc -2.55%$ -2.545 millions
Delcath Systems Inc -2.58%$ -2.577 millions
Imagenebio Inc -2.59%$ -2.591 millions
Therapeuticsmd Inc -2.68%$ -2.683 millions
Ngm Biopharmaceuticals Inc -2.91%$ -2.906 millions
Livanova Plc-3.00%$ -3.000 millions
Lifevantage Corp-3.04%$ -3.037 millions
Reata Pharmaceuticals Inc -3.18%$ -3.178 millions
Becton Dickinson And Company-3.20%$ -3.200 millions


About Musclepharm Revenue Growth Rates (MSLP), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Musclepharm Corp (CIK 1415684).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-22-013900
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Musclepharm Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.